{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:07:52Z","timestamp":1792213672870,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s12328-013-0447-1","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T18:21:05Z","timestamp":1390501265000},"page":"19-26","source":"Crossref","is-referenced-by-count":27,"title":["Management of hepatitis B virus-related acute liver failure"],"prefix":"10.1007","volume":"7","author":[{"given":"Makoto","family":"Oketani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"447_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1872-034X.2008.00322.x","volume":"38","author":"K Fujiwara","year":"2008","unstructured":"Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646\u201357.","journal-title":"Hepatol Res"},{"key":"447_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1872-034X.2012.01105.x","volume":"43","author":"M Oketani","year":"2013","unstructured":"Oketani M, Ido A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97\u2013105.","journal-title":"Hepatol Res"},{"key":"447_CR3","first-page":"82","volume":"12","author":"NY Heo","year":"2006","unstructured":"Heo NY, Lim YS, Kang JM, Oh SI, Park CS, Jung SW, et al. Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea. Korean J Hepatol. 2006;12:82\u201392.","journal-title":"Korean J Hepatol"},{"issue":"Suppl 1","key":"447_CR4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-1746.2010.06574.x","volume":"26","author":"M Oketani","year":"2011","unstructured":"Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol. 2011;26(Suppl 1):65\u201371.","journal-title":"J Gastroenterol Hepatol"},{"key":"447_CR5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.20703","volume":"41","author":"J Polson","year":"2005","unstructured":"Polson J, Lee WM. American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179\u201397.","journal-title":"Hepatology"},{"key":"447_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","volume":"3","author":"SK Sarin","year":"2009","unstructured":"Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269\u201382.","journal-title":"Hepatol Int"},{"key":"447_CR7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1478-3231.2012.02790.x","volume":"33","author":"KA Wlodzimirow","year":"2013","unstructured":"Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int. 2013;33:40\u201352.","journal-title":"Liver Int"},{"key":"447_CR8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00535-012-0624-x","volume":"47","author":"K Sugawara","year":"2012","unstructured":"Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849\u201361.","journal-title":"J Gastroenterol"},{"key":"447_CR9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10620-006-3175-2","volume":"51","author":"M Kumar","year":"2006","unstructured":"Kumar M, Jain S, Sharma BC, Sarin SK. Differentiating acute hepatitis B from the first episode of symptomatic exacerbation of chronic hepatitis B. Dig Dis Sci. 2006;51:594\u20139.","journal-title":"Dig Dis Sci"},{"key":"447_CR10","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA. 2004;101:6669\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"447_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.23230","volume":"51","author":"J Lucifora","year":"2010","unstructured":"Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology. 2010;51:63\u201372.","journal-title":"Hepatology"},{"key":"447_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1172\/JCI115590","volume":"89","author":"SL Tsai","year":"1992","unstructured":"Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest. 1992;89:87\u201396.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"447_CR13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/liv.12055","volume":"33","author":"S Pol","year":"2013","unstructured":"Pol S. Management of HBV in immunocompromised patients. Liver Int. 2013;33(Suppl 1):182\u20137.","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"447_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","volume":"31","author":"B Roche","year":"2011","unstructured":"Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31(Suppl 1):104\u201310.","journal-title":"Liver Int"},{"key":"447_CR15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2893.2005.00581.x","volume":"12","author":"CT Wai","year":"2005","unstructured":"Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005;12:192\u20138.","journal-title":"J Viral Hepat"},{"key":"447_CR16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJM199106133242404","volume":"324","author":"M Omata","year":"1991","unstructured":"Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991;324:1699\u2013704.","journal-title":"N Engl J Med"},{"key":"447_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-122-4-199502150-00001","volume":"122","author":"S Sato","year":"1995","unstructured":"Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med. 1995;122:241\u20138.","journal-title":"Ann Intern Med"},{"key":"447_CR18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1872-034X.2009.00519.x","volume":"39","author":"A Kusakabe","year":"2009","unstructured":"Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res. 2009;39:648\u201356.","journal-title":"Hepatol Res"},{"key":"447_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcv.2012.06.011","volume":"55","author":"J Inoue","year":"2012","unstructured":"Inoue J, Ueno Y, Kawamura K, Yamamoto T, Mano Y, Miura M, et al. Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis. J Clin Virol. 2012;55:147\u201352.","journal-title":"J Clin Virol"},{"key":"447_CR20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.510260235","volume":"26","author":"T Pollicino","year":"1997","unstructured":"Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997;26:495\u20139.","journal-title":"Hepatology"},{"key":"447_CR21","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/S0016-5085(97)70018-0","volume":"113","author":"CT Bock","year":"1997","unstructured":"Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology. 1997;113:1976\u201382.","journal-title":"Gastroenterology"},{"key":"447_CR22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/jhep.2001.26516","volume":"34","author":"T Kalinina","year":"2001","unstructured":"Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology. 2001;34:385\u201394.","journal-title":"Hepatology"},{"key":"447_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0016-5085(85)90566-9","volume":"89","author":"IS Sheen","year":"1985","unstructured":"Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732\u20135.","journal-title":"Gastroenterology"},{"key":"447_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0168-8278(90)90069-4","volume":"10","author":"AS Lok","year":"1990","unstructured":"Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol. 1990;10:29\u201334.","journal-title":"J Hepatol"},{"key":"447_CR25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/376988","volume":"37","author":"MF Yuen","year":"2003","unstructured":"Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, et al. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin Infect Dis. 2003;37:593\u20137.","journal-title":"Clin Infect Dis"},{"key":"447_CR26","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/gut.52.11.1630","volume":"52","author":"T Imamura","year":"2003","unstructured":"Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003;52:1630\u20137.","journal-title":"Gut"},{"key":"447_CR27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/jmv.20661","volume":"78","author":"R Chauhan","year":"2006","unstructured":"Chauhan R, Kazim SN, Bhattacharjee J, Sakhuja P, Sarin SK. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol. 2006;78:1047\u201354.","journal-title":"J Med Virol"},{"key":"447_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/(SICI)1096-9071(199805)55:1<35::AID-JMV7>3.0.CO;2-P","volume":"55","author":"K Inoue","year":"1998","unstructured":"Inoue K, Yoshiba M, Sekiyama K, Okamoto H, Mayumi M. Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus. J Med Virol. 1998;55:35\u201341.","journal-title":"J Med Virol"},{"key":"447_CR29","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306\u201311.","journal-title":"Br J Cancer"},{"key":"447_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12185-009-0359-5","volume":"90","author":"S Kusumoto","year":"2009","unstructured":"Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13\u201323.","journal-title":"Int J Hematol"},{"key":"447_CR31","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura T, Tanaka E, Kiyosawa K, Kumada H. Japan de novo Hepatitis BRG. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52\u20136.","journal-title":"Clin Infect Dis"},{"key":"447_CR32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2893.2009.01239.x","volume":"17","author":"P Borentain","year":"2010","unstructured":"Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and\/or autologous stem cell transplantation for cancer. J Viral Hepat. 2010;17:807\u201315.","journal-title":"J Viral Hepat"},{"key":"447_CR33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2893.2000.00257.x","volume":"7","author":"W Yeo","year":"2000","unstructured":"Yeo W, Zhong S, Chan PK, Ho WM, Wong HT, Chan AS, et al. Sequence variations of precore\/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat. 2000;7:448\u201358.","journal-title":"J Viral Hepat"},{"key":"447_CR34","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1182\/blood-2004-09-3402","volume":"105","author":"CK Hui","year":"2005","unstructured":"Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood. 2005;105:2616\u20137.","journal-title":"Blood"},{"key":"447_CR35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","volume":"42","author":"M Oketani","year":"2012","unstructured":"Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627\u201336.","journal-title":"Hepatol Res"},{"key":"447_CR36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2006.06.011","volume":"37","author":"A Rodella","year":"2006","unstructured":"Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol. 2006;37:206\u201312.","journal-title":"J Clin Virol"},{"key":"447_CR37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jmv.10291","volume":"69","author":"VP Chulanov","year":"2003","unstructured":"Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol. 2003;69:313\u201323.","journal-title":"J Med Virol"},{"key":"447_CR38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep.24732","volume":"55","author":"DY Dao","year":"2012","unstructured":"Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology. 2012;55:676\u201384.","journal-title":"Hepatology"},{"key":"447_CR39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2893.2005.00695.x","volume":"13","author":"HL Tillmann","year":"2006","unstructured":"Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256\u201363.","journal-title":"J Viral Hepat"},{"key":"447_CR40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1478-3231.2004.0983.x","volume":"24","author":"H Schmilovitz-Weiss","year":"2004","unstructured":"Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004;24:547\u201351.","journal-title":"Liver Int"},{"key":"447_CR41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","volume":"45","author":"M Kumar","year":"2007","unstructured":"Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97\u2013101.","journal-title":"Hepatology"},{"key":"447_CR42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1478-3231.2011.02450.x","volume":"31","author":"JW Yu","year":"2011","unstructured":"Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011;31:499\u2013506.","journal-title":"Liver Int"},{"key":"447_CR43","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1046\/j.1365-2036.2001.01107.x","volume":"15","author":"SW Tsang","year":"2001","unstructured":"Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther. 2001;15:1737\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"447_CR44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2893.2002.00385.x","volume":"9","author":"HL Chan","year":"2002","unstructured":"Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat. 2002;9:424\u20138.","journal-title":"J Viral Hepat"},{"key":"447_CR45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1440-1746.2004.03534.x","volume":"20","author":"A Tsubota","year":"2005","unstructured":"Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"447_CR46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","volume":"38","author":"RN Chien","year":"2003","unstructured":"Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322\u20137.","journal-title":"J Hepatol"},{"key":"447_CR47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10620-011-2013-3","volume":"57","author":"DY Dao","year":"2012","unstructured":"Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM, et al. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci. 2012;57:1349\u201357.","journal-title":"Dig Dis Sci"},{"key":"447_CR48","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","volume":"44","author":"RJ Colonno","year":"2006","unstructured":"Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656\u201365.","journal-title":"Hepatology"},{"key":"447_CR49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000236009","volume":"80","author":"C Jochum","year":"2009","unstructured":"Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009;80:235\u201340.","journal-title":"Digestion"},{"key":"447_CR50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1499-3872(13)60025-9","volume":"12","author":"J Lai","year":"2013","unstructured":"Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure. Hepatobiliary Pancreat Dis Int. 2013;12:154\u20139.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"447_CR51","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s10620-010-1257-7","volume":"55","author":"YL Cui","year":"2010","unstructured":"Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373\u201380.","journal-title":"Dig Dis Sci"},{"key":"447_CR52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/MCG.0b013e31819c3945","volume":"43","author":"SM Cohen","year":"2009","unstructured":"Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009;43:1008\u201310.","journal-title":"J Clin Gastroenterol"},{"key":"447_CR53","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.24109","volume":"53","author":"H Garg","year":"2011","unstructured":"Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774\u201380.","journal-title":"Hepatology"},{"key":"447_CR54","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1440-1746.2006.04630.x","volume":"22","author":"AJ Thompson","year":"2007","unstructured":"Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007;22:1078\u201385.","journal-title":"J Gastroenterol Hepatol"},{"key":"447_CR55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7150\/ijms.9.27","volume":"9","author":"T Kanda","year":"2012","unstructured":"Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, et al. Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. Int J Med Sci. 2012;9:27\u201332.","journal-title":"Int J Med Sci"},{"key":"447_CR56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u20132.","journal-title":"Hepatology"},{"key":"447_CR57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The L","year":"2012","unstructured":"European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"447_CR58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF01642872","volume":"13","author":"F Milazzo","year":"1985","unstructured":"Milazzo F, Galli M, Fassio PG, Cargnel A, Pugliese A, Tovo PA, et al. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection. 1985;13:130\u20133.","journal-title":"Infection"},{"key":"447_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0168-8278(87)80574-3","volume":"5","author":"JM Sanchez-Tapias","year":"1987","unstructured":"Sanchez-Tapias JM, Mas A, Costa J, Bruguera M, Mayor A, Ballesta AM, et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol. 1987;5:205\u201310.","journal-title":"J Hepatol"},{"key":"447_CR60","first-page":"671","volume":"48","author":"SS Kundu","year":"2000","unstructured":"Kundu SS, Kundu AK, Pal NK. Interferon-alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India. 2000;48:671\u20133.","journal-title":"J Assoc Physicians India"},{"key":"447_CR61","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2893.1997.00072.x","volume":"4","author":"NC Tassopoulos","year":"1997","unstructured":"Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M, Hadziyannis SJ. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat. 1997;4:387\u201394.","journal-title":"J Viral Hepat"},{"key":"447_CR62","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/MEG.0000000000000000","volume":"25","author":"K Fujiwara","year":"2013","unstructured":"Fujiwara K, Yasui S, Yokosuka O. Corticosteroid for severe acute exacerbation of chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25:1492.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"447_CR63","doi-asserted-by":"crossref","unstructured":"Fujiwara K, Yasui S, Yonemitsu Y, Mikata R, Arai M, Kanda T et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2013. doi: 10.1111\/hepr.12148 .","DOI":"10.1111\/hepr.12148"},{"key":"447_CR64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1872-034X.2010.00740.x","volume":"41","author":"XQ Zhang","year":"2011","unstructured":"Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46\u201353.","journal-title":"Hepatol Res"},{"key":"447_CR65","doi-asserted-by":"crossref","unstructured":"Chen JF, Wang KW, Zhang SQ, Lei ZY, Xie JQ, Zhu JY, et al. Dexamethasone can not improve outcome of patients with HBV related acute-on-chronic liver failure (ACLF). J Gastroenterol Hepatol. 2013. doi: 10.1111\/jgh.12454 .","DOI":"10.1111\/jgh.12454"},{"key":"447_CR66","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/lt.23469","volume":"18","author":"N Yamashiki","year":"2012","unstructured":"Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;18:1069\u201377.","journal-title":"Liver Transpl"},{"key":"447_CR67","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12072-009-9148-8","volume":"3","author":"AC Chan","year":"2009","unstructured":"Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int. 2009;3:571\u201381.","journal-title":"Hepatol Int"},{"key":"447_CR68","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-150-2-200901200-00100","volume":"150","author":"MF Sorrell","year":"2009","unstructured":"Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150:104\u201310.","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"447_CR69","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/lt.21614","volume":"14","author":"PW Angus","year":"2008","unstructured":"Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin\/antiviral regimen? Liver Transpl. 2008;14(Suppl 2):S15\u201322.","journal-title":"Liver Transpl"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-013-0447-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-013-0447-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-013-0447-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:57:28Z","timestamp":1559462248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-013-0447-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1007\/s12328-013-0447-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]}}}